Rixubis 3000 Unit (Nonacog Gamma KIT) 3000 UNIT

RIXUBIS 3000 Unit is a coagulation factor IX replacement therapy used for hemophilia B management. This intravenous kit helps control bleeding episodes and prevent complications.

Strength

3000 UNIT

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

RIXUBIS 3000 Unit is primarily used for the treatment and prevention of bleeding episodes in patients with hemophilia B, a genetic disorder that affects blood clotting. It works by replacing the missing clotting factor IX, which is essential for normal blood coagulation. This medication is often used in situations where bleeding control is critical, such as during surgery or after an injury.

Side Effects

Common effects of RIXUBIS 3000 Unit may include localized reactions at the injection site, such as redness, swelling, or discomfort. Some users may also experience mild to moderate allergic reactions, including rash or itching. These effects are generally temporary and resolve on their own.

Precautions & Warnings

RIXUBIS 3000 Unit should be handled with care and administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before use. Proper storage and handling instructions should be followed to maintain the efficacy of the medication.

Avoid Interactions

RIXUBIS 3000 Unit may interact with other medications, particularly those that affect blood clotting. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.

Frequently Asked Questions

RIXUBIS 3000 Unit is used to manage and prevent bleeding episodes in patients with hemophilia B.

RIXUBIS 3000 Unit is administered intravenously, typically by a healthcare professional.

Common side effects may include localized reactions at the injection site, such as redness or swelling.

Yes, RIXUBIS 3000 Unit is often used to control bleeding during surgical procedures in patients with hemophilia B.

Long-term use should be discussed with a healthcare provider to monitor for any potential complications.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.